Biopharmaceuticals firms Bristol-Myers Squibb (BMS) and ImClone Systems are to work with UK personalised medicine company DxS to further develop a K-RAS companion diagnostic for cancer drug Erbitux. The firms will work on DxS’ TheraScreen mutation kit to determine metastatic ...
Please Login to read the full article.
